- Home
- SNGX vs PAVM Comparison
SNGX vs PAVM Comparison
Compare SNGX & PAVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- PAVM
- Stock Information
- Founded
- SNGX 1987
- PAVM 2014
- Country
- SNGX United States
- PAVM United States
- Employees
- SNGX N/A
- PAVM N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- PAVM Medical/Dental Instruments
- Sector
- SNGX Health Care
- PAVM Health Care
- Exchange
- SNGX Nasdaq
- PAVM Nasdaq
- Market Cap
- SNGX 7.4M
- PAVM 7.2M
- IPO Year
- SNGX 1987
- PAVM 2016
- Fundamental
- Price
- SNGX $2.28
- PAVM $0.62
- Analyst Decision
- SNGX
- PAVM Strong Buy
- Analyst Count
- SNGX 0
- PAVM 1
- Target Price
- SNGX N/A
- PAVM $19.00
- AVG Volume (30 Days)
- SNGX 621.7K
- PAVM 126.7K
- Earning Date
- SNGX 03-14-2025
- PAVM 03-25-2025
- Dividend Yield
- SNGX N/A
- PAVM N/A
- EPS Growth
- SNGX N/A
- PAVM N/A
- EPS
- SNGX N/A
- PAVM 0.53
- Revenue
- SNGX $364,183.00
- PAVM $4,034,000.00
- Revenue This Year
- SNGX N/A
- PAVM $52.90
- Revenue Next Year
- SNGX $76.64
- PAVM $248.84
- P/E Ratio
- SNGX N/A
- PAVM $1.16
- Revenue Growth
- SNGX N/A
- PAVM 166.27
- 52 Week Low
- SNGX $1.83
- PAVM $0.57
- 52 Week High
- SNGX $14.88
- PAVM $3.50
- Technical
- Relative Strength Index (RSI)
- SNGX 36.12
- PAVM 39.43
- Support Level
- SNGX $2.23
- PAVM $0.62
- Resistance Level
- SNGX $2.39
- PAVM $0.66
- Average True Range (ATR)
- SNGX 0.17
- PAVM 0.05
- MACD
- SNGX 0.01
- PAVM 0.01
- Stochastic Oscillator
- SNGX 22.12
- PAVM 33.52
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.